Ads
related to: acute myeloid leukemia (aml)- Dosing & Monitoring
Twice Daily
Oral Dosing.
- Mechanism of Action
Inhibits Mutant IDHI and
Restores Myeloblast Differentiation
- Efficacy
Durable Complete Remissions
for R/R AML Patients.
- Access & Resources
Support is Available for
You and Your Patients.
- Dosing & Monitoring
Search results
Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival:...
Medical Xpress· 6 days agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...
Aptose Reports Results for the First Quarter 2024
Digital Journal· 6 hours agoTUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed ...
Researchers discover new target for potential leukemia therapy
Medical Xpress· 6 days agoThe study provides both mechanistic and preclinical evidence supporting the rapid initiation of...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 1 day agoThe company has secured a composition of matter patent for Annamycin, ensuring market exclusivity...
Sutro Biopharma shares hold on luvelta prospects By Investing.com
Investing.com· 12 hours agoAdditionally, Sutro Biopharma plans to initiate the REFRaME-P1 pediatric study in the second half of...
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
NBC 17 Raleigh· 6 days agoMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
Curis Announces Additional Data from TakeAim Leukemia Study
WRBL Columbus· 6 hours agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from ...
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell...
Nature· 6 days agoT cells are important for the control of acute myeloid leukemia (AML), a common and often deadly malignancy. We observed ...
Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show
MedPage Today· 6 days agoVenetoclax (Venclexta) combined with a hypomethylating agent (HMA) -- the standard of care for older...
Philadelphia jury awards former mechanic $725.5M in Exxon Mobil case
Philly.com· 4 days agoA Philadelphia jury sided against Exxon Mobil Corp. and awarded $725.5 million on Thursday to a...